Actively Recruiting
A Study in Adults With Desmoid Tumors
Led by Elpiscience (Suzhou) Biopharma, Ltd. · Updated on 2026-04-30
50
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open-label, multicenter, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, tolerability, patient-reported outcomes (PROs), pharmacokinetics (PK), anti-drug antibody (ADA) and pharmacodynamics (PD) of ES014 in adult desmoid tumor patients.
CONDITIONS
Official Title
A Study in Adults With Desmoid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed desmoid tumor.
- Within 12 months prior to enrollment, tumor target lesion growth ≥ 20% or new lesions appeared; or desmoid tumor-related pain not controlled by non-opioid medications.
- Either recurrence or progression after at least one treatment (surgery, radiotherapy, systemic therapy) or treatment-naive but suitable for study drug.
- At least one measurable lesion per RECIST v1.1.
- ECOG Performance Status score of 0-2.
- Life expectancy of at least 12 weeks.
- Adequate hematologic, liver, kidney, and coagulation function.
- Males and females of childbearing potential must abstain or use highly effective contraception.
You will not qualify if you...
- Prior therapy targeting CD39, CD73, adenosine A2A receptor, or TGF-β.
- Use of investigational agents or devices within 4 weeks before first study dose.
- Recent anticancer therapy within 28 days or 5 half-lives (minimum 14 days) before study drug.
- Recent radiotherapy within 2 weeks (limb) or 4 weeks (chest, brain, visceral organs) before study drug.
- Use of certain traditional Chinese medicines with anti-tumor effects within 14 days before study drug.
- Prior bone marrow or solid organ transplantation.
- Unresolved treatment-related toxicities above grade 1 (except alopecia, grade ≤2 neuropathy, or irreversible toxicities per investigator).
- Major surgery within 4 weeks before first study dose.
- Live vaccination within 4 weeks before first study dose.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
Research Team
J
Jiayu Song
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here